Ajuben 12 Tablet
Deutetrabenazine
12 mg
Incepta Pharmaceuticals Ltd.
| Pack size | 10's |
|---|---|
| Unite Price | 130 BDT |
Indications
Ajuben 12 Tablet is used for:
Indicated for chorea associated with Huntington disease, Tardive Dyskinesia
Adult Dose
Chorea
Indicated for chorea associated with Huntington disease
Dose is determined individually for each patient based on reduction of chorea and tolerability
Initial dose when not being switched from tetrabenazine: 6 mg PO qDay
May increased dose at weekly intervals in increments of 6 mg/day; not to exceed 48 mg/day
Administer doses >12 mg/day in 2 divided doses
Tardive Dyskinesia
Indicated for treatment of tardive dyskinesia (TD)
Dose is determined individually for each patient based on reduction of TD and tolerability
Initial dose when not being switched from tetrabenazine: 6 mg PO BID
May increased dose at weekly intervals in increments of 6 mg/day; not to exceed 48 mg/day
Hepatic impairment
Contraindicated
Effect of hepatic impairment on the pharmacokinetics of deutetrabenazine and its primary metabolites has not been studied
In a clinical study conducted with tetrabenazine, a closely related VMAT2 inhibitor, there was a large increase in exposure to tetrabenazine and its active metabolites
The clinical significance of this increased exposure has not been assessed, but because of concerns for a greater risk for serious adverse reactions, it is contraindicated
Child Dose
Renal Dose
Administration
Administer with food
Swallow tablet whole; do not chew, crush, or break
Contra Indications
Patients with Huntington disease who are suicidal, or in patients with untreated or inadequately treated depression
Hepatic impairment
Coadministration with MAOIs; deutetrabenazine should not be used in combination with an MAOI or within 14 days of discontinuing an MAOI
Coadministration with reserpine; at least 20 days should elapse after stopping reserpine before initiating deutetrabenazine
Coadministration with tetrabenazine or valbenazine
Precautions
Huntington disease is a progressive disorder characterized by changes in mood, cognition, chorea, rigidity, and functional capacity over time; VMAT2 inhibitors, including deutetrabenazine, may cause a worsening in mood, cognition, rigidity, and functional capacity; periodically reevaluate the need for deutetrabenazine by assessing effect on chorea and adverse effects
Patients with Huntington disease are at increased risk for depression and suicidality; deutetrabenazine may increase this risk.
May increase the risk of akathisia, agitation, and restlessness in patients with Huntington’s disease and tardive dyskinesia; reduce dose or discontinue if this occurs
Sedation/somnolence reported; may impair patient’s ability to drive or operate complex machinery
Pregnancy-Lactation
Pregnancy
There are no adequate data on the developmental risk in pregnant women
Animal studies
Administration of deutetrabenazine to rats during organogenesis produced no clear adverse effect on embryofetal development
However, administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality
Lactation
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Coadministration with dopamine antagonists or antipsychotics may increase risk for parkinsonism, NMS, and akathisia
Coadministration with alcohol and other sedating drugs may worsen somnolence associated with deutetrabenazine
Side Effects
Side effects of Deutetrabenazine :
>10%
Somnolence (11%)
1-10%
Diarrhea (9%)
Dry mouth (9%)
Fatigue (9%)
Urinary tract infection (7%)
Insomnia (7%)
Anxiety (4%)
Constipation (4%)
Contusion (4%)
Dizziness (4%)
Akathisia, agitation, or restlessness (4%)
Depression in patients with Huntington’s disease (4%)
Suicidal ideation in patients with Huntington’s disease (2%)
Parkinsonism in patients with Huntington’s disease
Mode of Action
Oral vesicular monoamine transporter-2 (VMAT-2) inhibitor; decreases uptake of monoamines (eg, dopamine, serotonin, norepinephrine, histamine) into synaptic vesicles and depletes monoamine stores from nerve terminals
The precise mechanism by which deutetrabenazine exerts its antichorea effects is unknown, but is believed to be related to its effect on reversible depletion of monoamines from nerve terminals
Note
Ajuben 12 12 mg Tablet generic name is Deutetrabenazine. Ajuben 12 12 mg Tablet is manufactured by Incepta Pharmaceuticals Ltd.Ajuben 12 is availble in all over Bangladesh.
Mes BD drug index information on Ajuben 12 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.